DeepNaps
深纳普思
DeepNaps (深纳普思, also known as Synapsor) is an AI-powered chronic disease management platform founded by CEO Wang Zhihua, a PhD in computer science from Oxford University with a master's from Cambridge . The company develops wearable medical devices combined with neural network algorithms, aiming to build normalized chronic disease management systems . In December 2021, DeepNaps raised a new round of funding in the tens of millions of dollars, led by Xiaomi Group with follow-on investments from Source Code Capital and Shunwei Capital; Source Code Capital had also led its angel round . The company was about two years old at that time, with over 70% of its staff in R&D and more than half holding master's or doctoral degrees . elsewheres corpus does not cover more recent developments.
AI-generated — may contain errors, please verify.
Coverage
MaHui | Nearly 40 MaHui Members Named to 36Kr's X·36Under36 S-Class Young Entrepreneurs List
Source Code Capital portfolio company Silicon Integrated announced the completion of a Series D funding round worth several hundred million yuan, with existing investor Source Code Capital continuing to increase its stake.
An innovative chip design company with independent, self-developed intellectual property.
AI Medical Device Company "Silicon Based Bionics" Raises Over 800 Million Yuan in Three C-Round Tranches, Led by Source Code Capital
China's first CGM company to receive regulatory approval and achieve mass production without requiring finger-prick calibration
AI-powered molecular simulation company **DeepWise** announced the completion of a Series B funding round of tens of millions of dollars, co-led by **Source Code Capital**.
Building a next-generation microscale industrial design platform to unlock R&D and manufacturing productivity across the industry.
Source Code Capital portfolio company Standard Robots announced the completion of a Pre-C funding round worth several hundred million RMB, with existing shareholder Source Code Capital continuing to increase its stake.
Based on the "WIPE" strategy, targeting the global market.
Digital therapeutics company IBT无疆科技 announced the completion of its Pre-A+ funding round, with existing investor Source Code Capital continuing to increase its stake.
Advancing the Commercialization of Next-Generation Digital Therapeutics
AI Chronic Disease Management Platform DeepNaps Announces New Round of Funding in the Tens of Millions of Dollars, Existing Investor Source Code Capital Continues to Increase Stake
In the future, it aims to serve 50% of China's chronic disease patients.
